Adam Joseph Mead

Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom.

We Are Pioneer Group Ltd. (Pioneer Group) is a venture capital firm founded in 2021. The firm is headquartered in London, United Kingdom.

Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom.

AlveoGene Ltd. is a British dormant company that was founded in 2022. The company is based in Oxford, UK.

Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Kinomica Ltd. develops anti-cancer drug therapies. The company is based in Macclesfield, UK. The British company was founded in 2016 by David Britton, Pedro Rodriguez Cutillas. The CEO is Jane Theaker.

metaLinear Ltd. operates as a biotechnology firm. It uses proteome engineering technology to identify, validate, and drug new microbial targets. The company was founded by Paul Ko Ferrigno in November 2016 and is headquartered in Cheshire, the United Kingdom.

Dark Blue Therapeutics Ltd. operates as a biotechnology firm. The company was founded in June 4, 2020 an is headquartered in Oxford, the United Kingdom.

NanoSyrinx Ltd is a discovery stage biotechnology company that is based in the UK. The British company is focused on developing protein nanosyringes as a new way to deliver protein and peptide biologic drugs intracellularly. The company uses synthetic biology approaches to achieve this goal. The company was founded by Joseph Healey, Alexia Hapeshi, and Nicholas Waterfield, with Joseph Healey serving as the CEO since incorporation.

Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom.

BioCity Group Ltd (BioCity) is a venture capital firm founded in 2002. The firm is headquartered in London, United Kingdom.

Fast BioPharma Ltd. develops therapeutic products for treatment of cancer. The company is headquartered in Watlington, the United Kingdom.

Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland.

Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.

Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom.